ZoeNCure Therapeutics secures a follow-on seed investment of INR 20 crore to accelerate its next-generation antibody drug conjugate (ADC) program, according to reports. The funding is described as being led by the HNI (high-net-worth individual) Tyagi Family.
The outlets also state that this round brings the company’s total capital raised to date to INR 22.5 crore. Both sources frame the move as reflecting investor confidence in ZoeNCure’s efforts to advance its ADC pipeline. They do not provide additional details on the stage of the technology, the timeline for development, or whether the investment includes specific milestones.
While both articles present the same core facts—amount, investor lead, and updated total funding—no notable differing angles are apparent in the available text.
